Investigational glucagon-like peptide-1 agonists for the treatment of obesity

Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong Min Liu

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Introduction: Obesity is a worldwide problem predisposing to type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, cancer and other comorbidities. Lifestyle modification is the first line intervention but adjunctive pharmacotherapy is often required. The GLP-1 receptor agonists (GLP-1RAs) were developed primarily for T2DM and they also reduce body weight. Liraglutide was approved for the treatment of obesity and other GLP-1RAs are likely to be suitable for this indication. Areas covered: This review describes the GLP-1RAs that have been approved for the treatment of T2DM as potential candidates for the treatment of obesity and the new agents currently under development which may have advantages in patient adherence. Expert opinion: The GLP-1RAs offer a welcome addition to obesity pharmacotherapy. They appear to be free of serious adverse effects although uncertainty remains about possible risks of pancreatitis and neoplasms. However, they have frequent gastrointestinal side effects, particularly nausea, which limits their tolerability. Cardiovascular outcome studies in T2DM support their use and this is likely to increase in both T2DM and obesity. Other GLP-1RAs which can be given by subcutaneous injection once weekly or less frequently or by oral administration would have advantages especially if nausea is less frequent than with liraglutide.

Original languageEnglish
Pages (from-to)1167-1179
Number of pages13
JournalExpert Opinion on Investigational Drugs
Volume25
Issue number10
DOIs
Publication statusPublished - Oct 2 2016

Fingerprint

Glucagon-Like Peptide 1
Type 2 Diabetes Mellitus
Obesity
Nausea
Therapeutics
Drug Therapy
Expert Testimony
Subcutaneous Injections
Patient Compliance
Pancreatitis
Uncertainty
Oral Administration
Life Style
Comorbidity
Neoplasms
Cardiovascular Diseases
Body Weight
Outcome Assessment (Health Care)
Glucagon-Like Peptide-1 Receptor
Hypertension

Keywords

  • Efpeglenatide
  • exenatide
  • GLP-1 receptor agonist
  • ITCA 650
  • liraglutide
  • obesity
  • semaglutide

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Investigational glucagon-like peptide-1 agonists for the treatment of obesity. / Tomlinson, Brian; Hu, Miao; Zhang, Yuzhen; Chan, Paul; Liu, Zhong Min.

In: Expert Opinion on Investigational Drugs, Vol. 25, No. 10, 02.10.2016, p. 1167-1179.

Research output: Contribution to journalReview article

Tomlinson, Brian ; Hu, Miao ; Zhang, Yuzhen ; Chan, Paul ; Liu, Zhong Min. / Investigational glucagon-like peptide-1 agonists for the treatment of obesity. In: Expert Opinion on Investigational Drugs. 2016 ; Vol. 25, No. 10. pp. 1167-1179.
@article{15e81b3565e0486c9f5d7ea1bea42bdf,
title = "Investigational glucagon-like peptide-1 agonists for the treatment of obesity",
abstract = "Introduction: Obesity is a worldwide problem predisposing to type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, cancer and other comorbidities. Lifestyle modification is the first line intervention but adjunctive pharmacotherapy is often required. The GLP-1 receptor agonists (GLP-1RAs) were developed primarily for T2DM and they also reduce body weight. Liraglutide was approved for the treatment of obesity and other GLP-1RAs are likely to be suitable for this indication. Areas covered: This review describes the GLP-1RAs that have been approved for the treatment of T2DM as potential candidates for the treatment of obesity and the new agents currently under development which may have advantages in patient adherence. Expert opinion: The GLP-1RAs offer a welcome addition to obesity pharmacotherapy. They appear to be free of serious adverse effects although uncertainty remains about possible risks of pancreatitis and neoplasms. However, they have frequent gastrointestinal side effects, particularly nausea, which limits their tolerability. Cardiovascular outcome studies in T2DM support their use and this is likely to increase in both T2DM and obesity. Other GLP-1RAs which can be given by subcutaneous injection once weekly or less frequently or by oral administration would have advantages especially if nausea is less frequent than with liraglutide.",
keywords = "Efpeglenatide, exenatide, GLP-1 receptor agonist, ITCA 650, liraglutide, obesity, semaglutide",
author = "Brian Tomlinson and Miao Hu and Yuzhen Zhang and Paul Chan and Liu, {Zhong Min}",
year = "2016",
month = "10",
day = "2",
doi = "10.1080/13543784.2016.1221925",
language = "English",
volume = "25",
pages = "1167--1179",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Investigational glucagon-like peptide-1 agonists for the treatment of obesity

AU - Tomlinson, Brian

AU - Hu, Miao

AU - Zhang, Yuzhen

AU - Chan, Paul

AU - Liu, Zhong Min

PY - 2016/10/2

Y1 - 2016/10/2

N2 - Introduction: Obesity is a worldwide problem predisposing to type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, cancer and other comorbidities. Lifestyle modification is the first line intervention but adjunctive pharmacotherapy is often required. The GLP-1 receptor agonists (GLP-1RAs) were developed primarily for T2DM and they also reduce body weight. Liraglutide was approved for the treatment of obesity and other GLP-1RAs are likely to be suitable for this indication. Areas covered: This review describes the GLP-1RAs that have been approved for the treatment of T2DM as potential candidates for the treatment of obesity and the new agents currently under development which may have advantages in patient adherence. Expert opinion: The GLP-1RAs offer a welcome addition to obesity pharmacotherapy. They appear to be free of serious adverse effects although uncertainty remains about possible risks of pancreatitis and neoplasms. However, they have frequent gastrointestinal side effects, particularly nausea, which limits their tolerability. Cardiovascular outcome studies in T2DM support their use and this is likely to increase in both T2DM and obesity. Other GLP-1RAs which can be given by subcutaneous injection once weekly or less frequently or by oral administration would have advantages especially if nausea is less frequent than with liraglutide.

AB - Introduction: Obesity is a worldwide problem predisposing to type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, cancer and other comorbidities. Lifestyle modification is the first line intervention but adjunctive pharmacotherapy is often required. The GLP-1 receptor agonists (GLP-1RAs) were developed primarily for T2DM and they also reduce body weight. Liraglutide was approved for the treatment of obesity and other GLP-1RAs are likely to be suitable for this indication. Areas covered: This review describes the GLP-1RAs that have been approved for the treatment of T2DM as potential candidates for the treatment of obesity and the new agents currently under development which may have advantages in patient adherence. Expert opinion: The GLP-1RAs offer a welcome addition to obesity pharmacotherapy. They appear to be free of serious adverse effects although uncertainty remains about possible risks of pancreatitis and neoplasms. However, they have frequent gastrointestinal side effects, particularly nausea, which limits their tolerability. Cardiovascular outcome studies in T2DM support their use and this is likely to increase in both T2DM and obesity. Other GLP-1RAs which can be given by subcutaneous injection once weekly or less frequently or by oral administration would have advantages especially if nausea is less frequent than with liraglutide.

KW - Efpeglenatide

KW - exenatide

KW - GLP-1 receptor agonist

KW - ITCA 650

KW - liraglutide

KW - obesity

KW - semaglutide

UR - http://www.scopus.com/inward/record.url?scp=84988529979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988529979&partnerID=8YFLogxK

U2 - 10.1080/13543784.2016.1221925

DO - 10.1080/13543784.2016.1221925

M3 - Review article

C2 - 27563838

AN - SCOPUS:84988529979

VL - 25

SP - 1167

EP - 1179

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 10

ER -